Goldman Sachs initiated coverage of Alignment Healthcare (ALHC) with a Buy rating and $21 price target The managed care industry faces its most significant underwriting downturn in over 15 years, the analyst tells investors in a research note. Goldman recommends increased exposure to Medicare Advantage as it sees a margin recovery phase beginning in 2026. However, the firm does not see the Medicare Advantage recovery playing out uniformly across the group in 2026. The analyst also sees a longer path to cyclical recovery in Medicaid and the healthcare exchange.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Clover Health ‘loses big’ in CMS star ratings, says Leerink
- Alignment Healthcare announces 100% of MA members enrolled in 4+ stars plans
- Alignment Healthcare announces its 2026 product portfolio
- Alignment Healthcare’s Strong Star Ratings and Growth Potential Drive Buy Rating
- Alignment Healthcare falls -6.6%
